| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = -$210,934 ) |
| | 2026 | 2023 | STRM.BIO INCORPORATED | 750 MAIN ST | CAMBRIDGE | MA | 02139-3544 | MIDDLESEX | USA | R44TR004238 | Bone marrow-targeted extracellular vesicles as a novel non-viral gene editor delivery platform | 000 | 2 | NIH | 11/17/2025 | -$210,934 |
|
| Issue Date FY: 2023 ( Subtotal = $1,047,299 ) |
| | 2023 | 2023 | STRM.BIO INCORPORATED | 127 WESTERN AVE | ALLSTON | MA | 02134-1008 | SUFFOLK | USA | R44TR004238 | Bone marrow-targeted extracellular vesicles as a novel non-viral gene editor delivery platform | 000 | 2 | NIH | 6/1/2023 | $1,047,299 |
|
| Issue Date FY: 2022 ( Subtotal = $1,004,289 ) |
| | 2022 | 2022 | STRM.BIO INCORPORATED | 127 WESTERN AVE | ALLSTON | MA | 02134-1008 | SUFFOLK | USA | R44TR004238 | Bone marrow-targeted extracellular vesicles as a novel non-viral gene editor delivery platform | 000 | 1 | NIH | 6/30/2022 | $1,004,289 |
|
|
